Caricamento azienda
Just reported
Q3 FY2026 results
From Citius Oncology's results release of 26 ottobre 2026; its quarterly report has since been filed.
Revenue
Actual
1,5M USD
-10% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,08 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-8,7M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Citius Oncology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B USDA
NBIXNeurocrine Biosciences, Inc.16,9B USDA+
ELANElanco Animal Health Incorporated13,4B USDA
KNSAKiniksa Pharmaceuticals International, plc8,2B USDA+
LQDALiquidia Corporation5,2B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now A
Costruito dai documenti depositati da Citius Oncology, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
